Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Pharmos (PARS) -- Ignore unavailable to you. Want to Upgrade?

To: Zvi Steinberg who wrote (644)	3/19/1999 8:53:00 AM
From: yosi s	Respond to of 1386

Zvi Though it is nice that medicinal use of marijuana gets an exposure. HU 211, though a derivative from the same plant. Is to be used for a complete different indication, and is very different from THC and marinol. So yes it will be easier for Pharmos, yet there is no rational, for Pharmos to get on this bandwagon, too peripheral. It is more important to get exposure for its main indication TBI and stroke, as well as those indication where the Alpha 1 TNF comes in. ,(MS,Parkinson?, may be some autoimmune disorders ie. Ulcerative Colitis, and even Septic Shock, .) So we got great science without psychotropic effect.